CGH Spotlight Blog
This blog features content and images to showcase the great work from the Center for Global Health.
CGH is working with the International Agency for Research on Cancer (IARC) and the Pan American Health Organization (PAHO) on the ESTAMPA Study, a multi-centric study of cervical cancer screening and triage with HPV testing. This study compares screening of 50,000 women in 10 Latin American countries for visual, cytological, and molecular triage methods, or combination of these methods, for their performance and cost-effectiveness among women participating in HPV-based screening programs.
The ESTAMPA Study has already begun in Colombia, Paraguay, Honduras and Uruguay, and will begin soon in Costa Rica, Bolivia, Peru, and Argentina. It is also expected that Brazil, Mexico, and Ecuador will begin recruiting eligible women into the study within the year. The benefit of a study that aims to recruit such a large number of women is not only a comprehensive representation of the Latin American population, but the ESTAMPA study offers cervical cancer screening to women who otherwise may not have been ever screened and who may be at high risk of cervical cancer. Through its support of the ESTAMPA study, CGH promotes the regionally organized cervical cancer screening, unique to Latin America. CGH’s contributions include training for over forty cervical cancer researchers, pathologists, medical oncologists, and oncology nurses participating in the study; transferring both knowledge and technology while strengthening this valuable network of cancer researchers in the region.
The International Cancer Screening Network (ICSN) Meeting brings together individuals involved in cancer screening research and cancer screening programs from the ICSN’s member countries. The consortium meets once every two to three years, and began as a small group of 16 collaborators in 1997. In the most recent meeting of the ICSN, in Rotterdam from June 2-4, 2015, there were over 250 participants – a testament to growing interest in cancer screening. ICSN is composed of 23 countries, many of which are classified as high-income countries by the World Bank. To add a new dimension, CGH led the workshop session “Implementation Science Research for Cancer Screening in Low- and Middle-Income Countries” (LMICs), in an effort to expand the reach of the ICSN.
Dr. Sudha Sivaram began the afternoon by giving an introduction to implementation science, followed by our three invited speakers from LMICs: Dr. Mimi Raesima, from Botswana; Dr. Soo Teo, from Malaysia; and Dr. Partha Basu, from the International Agency of Research on Cancer, who has worked extensively in India. This group presented cancer epidemiology data from their respective countries and explained lessons they have learned in their work, as well as future opportunities for growth in national level cancer screening programs. Dr. Stephen Taplin, NCI, Division of Cancer Control and Population Sciences, concluded the morning session with his own experiences from the NCI, before participants broke into small groups to further connect with LMIC speakers.
NCI CGH was privileged to co-sponsor the 2015 International Symposium on Cancer Clinical Trials and related meetings held in partnership with the Japanese National Cancer Center (JNCC) and Embassies of France, Korea, United Kingdom (UK), and United States (US) in Tokyo on May 14 - 15, 2015.
On May14, 2015, Drs. Atsushi Ohtsu and Seiichiro Yamamoto of JNCC hosted an Experts’ Meeting that highlighted exciting research by Japanese and UK scientists. Dr. Takayuki Yoshino (JNCC) and Dr. Naoko Takebe (US NCI) introduced new precision medicine initiatives, and Drs. Timothy Yap, Hiroyoshi Nishikawa, and Samantha Turnbull presented their work on phase I trials and immunotherapy. This was followed by a meeting with cancer patient advocates hosted by Drs. Fumihiko Wakao and Seiichiro Yamamoto of JNCC. Here, Japanese patient advocates shared the need for more information and patient access to clinical trials, patient advocate training, and opportunities to provide input on clinical research. Drs. Ted Trimble, Matt Seymour, and François Sigaux presented on ways that patient advocates play an important role in cancer research in the US, UK, and France, respectively. This session was informative for everyone as participants heard examples for patient involvement that could be adopted in their own country.
Breast and cervical cancers are two leading causes of death among women worldwide. Countries in the northern Andean region face the highest mortality and incidence ratio for these cancers in Latin America. Poor outcomes in low- and middle-income countries have been attributed to a lack of awareness on the benefits of early detection and treatment, late stage detection, and limited access to cancer-related treatment.
In early spring the Center for Global Health saw the opportunity to better support Peru’s efforts in bringing attention to the role of education and advocacy in breast and cervical cancer prevention and control. Through partnerships with the Peruvian Ministry of Health and the Pan American Health Organization (PAHO) regional office, the first Women’s Cancer Summit was held in Lima, Peru. This unique training workshop brought primary-level health care providers from 26 districts together with patient advocates and survivors from Peru, Bolivia, Colombia, and Ecuador.
Indonesia boasts some of the highest smoking rates in the world. The Global Adult Tobacco Survey (GATS), conducted in 2011 by the Indonesian National Institute of Health Research and Development and the U.S. Center for Disease Control and Prevention, showed that more than 67% of men and almost 40% of boys aged 13-15 use tobacco.
The numbers are staggering. If left unchecked, tobacco-related illness will wreak havoc on Indonesia's health system. In 2014, the Government of Indonesia implemented universal health care that will provide unprecedented levels of health coverage to the Indonesian population.. If tobacco use rates continue at current levels, chronic diseases such as cancer will economically burden this system in yet untold ways.
Mexico’s National Cancer Institute, Instituto Nacional de Cancerología (INCan), has been designated by its Secretaría de Salud (Secretary of Health) as the leading entity to coordinate the development and implementation of its first National Cancer Control Plan (NCCP). The National Cancer Institute and the Center for Global Health have had a long-standing and successful partnership with INCan, and at their request are identifying new or enhanced ways to provide technical support by way of resources, training, and collaborative programs to facilitate the implementation of the NCCP.
Mexican authorities recognize the need for strengthening their current health policies and integrating research to enhance cancer control efforts across the country. In addition, an emphasis has been placed on building capacity among healthcare professionals within the cancer community to better address the cancer burden in Mexico. To this end, cancer control and research experts from the National Cancer Institute, Center for Global Health; Division of Cancer Control and Population Sciences; and Division of Cancer Epidemiology and Genetics, and the Centers for Disease Control & Prevention are meeting with representatives from Secretaría de Salud, INCan, Instituto Nacional de Salud Pública (National Institute of Public Health), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (National Institute of Nutrition), and Instituto de Medicina Genómica (Institute of Genomic Medicine) in Mexico this week to discuss expanding existing and exploring new collaborations. Areas of interest include cancer control and epidemiology, tobacco control research, cancer research and education training, border health, joint research activities, and scientific journalism training.
Shady Grove celebrated Take Your Child To Work Day (TYCTWD) this year with a variety of activities and sessions aimed at inspiring school-aged children to explore career paths in science and public service. CGH took this opportunity to host its inaugural Take Your Child To Work Day session, An Introduction to Global Health. The session was overwhelmingly well received by kids and parents alike, as our theme prompted them to think about the importance of nutrition, healthy living, and science not only in their own lives, but in the lives of everyone around the world.
The 45-minute session, bringing together fifteen students ranging from 1st to 7th grade, began with a presentation by Dr. Lisa Stevens (Deputy Director Planning and Operations) and Cathy Muha (Branch Chief for Planning, Evaluation and Operations) highlighting the missions of the NIH, NCI, and CGH. The presentation concluded with CGH facilitators, Balkissa Abdoulaye; Elyse Gillen; Tom Gross; Catherine Hidalgo; Sudha Sivaram; and Hillary Topazian, each sharing with the group what they enjoyed most about working at CGH.
Follow Dr. Pearlman on Twitter
The NCI Center for Global Health hosted its first session at the 2015 annual meeting of the American Association for Cancer Research (AACR) last week in Philadelphia, Pennsylvania. The AACR is the world’s oldest and largest professional association related to cancer research, and its annual meeting is a veritable who’s who of cancer experts, industry leaders, and policy professionals. This year’s annual meeting included approximately 750 sessions and attracted 20,000 participants, fully overwhelming the Pennsylvania Convention Center in the ‘City of Brotherly Love’.
The NIH has recently awarded its first round of grants in a parallel U.S.-South Africa funding opportunity. Scientific cooperation between the U.S. and the Republic of South Africa was initiated in 1995, and has grown rapidly in recent years. Recognizing that enhanced cooperative biomedical research would be of mutual benefit to the U.S. and South Africa, the NIH Director and President of the South African Medical Research Council (SAMRC) signed a Memorandum of Understanding (MOU) in January, 2013 to develop a new U.S.-South Africa Program for Collaborative Biomedical Research. A working group, made up of members from both NIH and SAMRC developed strategic plans for collaboration, each allocating resources to support joint activities pursued under this program.
Initiatives funded through this program will advance biomedical research for tuberculosis and HIV/AIDS in not only the US and South Africa, but will contribute to the global wealth of knowledge of these diseases. Moreover, the scope of this initiative includes HIV/AIDS co-morbidities, and resulting malignancies. This opportunity was further targeted at expanding basic, translational, behavioral and applied research that will stimulate scientific discovery, and engage U.S. and South African researcher collaboration.
Cancer specific targets for this initiative include the following:
At its core, cancer research is about improving and saving lives of those afflicted by cancer. The Max Foundation, led by CEO and co-founder Pat Garcia-Gonzalez, has been widely credited with helping to save the lives of thousands of patients with chronic myeloid leukemia (CML) worldwide by helping patients access the cancer drug imatinib. Pat’s work to bring the fruits of cancer research to patients in low- and middle-income countries inspired the creation of the National Cancer Institute (NCI) Global Cancer Medicine Humanitarian Award; and she the award’s first honoree.
Pat Garcia-Gonzalez started the Max Foundation as a tribute to her step-son, Max, who was diagnosed with CML in 1988 at the age of 14 and passed away in 1991. Thirteen years following Max’s diagnosis, imatinib was approved by the U.S. Food and Drug Administration to treat CML patients. Pat saw imatinib’s enormous potential to allow many patients to live a normal lifestyle, but recognized that the drug’s high cost meant that many patients in low- and middle-income countries would have no access to this life-saving treatment. Despite tremendous hurdles, Pat and her team at the Max Foundation worked with the pharmaceutical company, Novartis, to establish a mechanism to provide imatinib to patients in low-resource settings.